Review

*Author for correspondence: Tel.: +44 141 548 3724;

E-mail Address: hanin.alyamani@strath.ac.uk

Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, G4 0RE Glasgow, United Kingdom

Search for more papers by this author

Mohammad A Obeid

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Yarmouk University, Shafiq Irshidat Street, 21163, Irbid, Jordan

Search for more papers by this author

Rothwelle J Tate

Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, G4 0RE Glasgow, United Kingdom

Search for more papers by this author

Valerie A Ferro

Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, G4 0RE Glasgow, United Kingdom

Search for more papers by this author

Published Online:7 Dec 2018https://doi.org/10.4155/tde-2018-0051

View article

Abstract

Exosomes are nanovesicles secreted by many cells, including cancer cells. Extensive research has been carried out to validate potential applications of exosomes and to evaluate their efficiency in a wide range of diseases, including cancer. The current knowledge on the origin, biogenesis and composition of exosomes is described. This review then focuses on the use of exosomes in cancer diagnostics and therapeutics.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12(5), 347–357 (2013).Crossref, Medline, CAS, Google Scholar
2 Yu D, Wu Y, Shen H et al. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 106(8), 959–964 (2015). www.ncbi.nlm.nih.gov/pubmed/26052865.Crossref, Medline, CAS, Google Scholar
3 Sundararajan V, Sarkar FH, Ramasamy TS. The versatile role of exosomes in cancer progression: diagnostic and therapeutic implications. Cell. Oncol. 41(3), 223–252 (2018). www.ncbi.nlm.nih.gov/pubmed/29667069. •• A comprehensive overview of exosome role in cancer progression, their potential diagnostic role as biomarkers and their therapeutic applications.Crossref, CAS, Google Scholar
4 Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38(6), 754–763 (2017). www.nature.com/doifinder/10.1038/aps.2017.12.Crossref, Medline, CAS, Google Scholar
5 Anderson HC. Vesicles associated with calcification in the matrix of epiphyseal cartilage. J. Cell Biol. 41(1), 59–72 (1969). ww.ncbi.nlm.nih.gov/pubmed/5775794.Crossref, Medline, CAS, Google Scholar
6 Crawford N. The presence of contractile proteins in platelet microparticles isolated from human and animal platelet-free plasma. Br. J. Haematol. 21(1), 53–69 (1971). www.ncbi.nlm.nih.gov/pubmed/4254312.Crossref, Medline, CAS, Google Scholar
7 Stegmayr B, Ronquist G. Promotive effect on human sperm progressive motility by prostasomes. Urol. Res. 10(5), 253–257 (1982). www.ncbi.nlm.nih.gov/pubmed/6219486.Crossref, Medline, CAS, Google Scholar
8 Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97(2), 329–339 (1983).Crossref, Medline, CAS, Google Scholar
9 Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 33(3), 967–978 (1983). www.ncbi.nlm.nih.gov/pubmed/6307529.Crossref, Medline, CAS, Google Scholar
10 Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J. Cell Biol. 101(3), 942–948 (1985).Crossref, Medline, CAS, Google Scholar
11 Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 262(19), 9412–9420 (1987).Crossref, Medline, CAS, Google Scholar
12 Huotari J, Helenius A. Endosome maturation. EMBO J. 30(17), 3481–500 (2011). www.ncbi.nlm.nih.gov/pubmed/21878991.Crossref, Medline, CAS, Google Scholar
13 Klumperman J, Raposo G. The complex ultrastructure of the endolysosomal system. Cold Spring Harb. Perspect. Biol. (2014). http://cshperspectives.cshlp.org/content/early/2014/05/22/cshperspect.a016857.short%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/24851870.Crossref, Medline, Google Scholar
14 Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 29C, 116–125 (2014). www.sciencedirect.com/science/article/pii/S095506741400057X.Crossref, Google Scholar
15 Abels ER, Breakefield XO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell. Mol. Neurobiol. 36(3), 301–312 (2016). www.ncbi.nlm.nih.gov/pubmed/27053351.Crossref, Medline, CAS, Google Scholar
16 Frankel EB, Audhya A. ESCRT-dependent cargo sorting at multivesicular endosomes. Semin. Cell Dev. Biol. 74, 4–10 (2018). https://linkinghub.elsevier.com/retrieve/pii/S1084952117300113.Crossref, Medline, CAS, Google Scholar
17 Colombo M, Moita C, van Niel G et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J. Cell Sci. 126(Pt 24), 5553–5565 (2013). http://www.ncbi.nlm.nih.gov/pubmed/24105262.Crossref, Medline, CAS, Google Scholar
18 Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458(7237), 445–452 (2009). http://www.ncbi.nlm.nih.gov/pubmed/19325624.Crossref, Medline, CAS, Google Scholar
19 Juan T. Biogenesis and function of ESCRT-dependent extracellular vesicles. Semin. Cell Dev. Biol. 74, 66–77 (2018). www.sciencedirect.com/science/article/pii/S1084952117302525.Crossref, Medline, CAS, Google Scholar
20 Buschow SI, Liefhebber JMP, Wubbolts R, Stoorvogel W. Exosomes contain ubiquitinated proteins. Blood Cells Mol. Dis. 35(3), 398–403 (2005).Crossref, Medline, CAS, Google Scholar
21 Palicharla VR, Maddika S. HACE1 mediated K27 ubiquitin linkage leads to YB-1 protein secretion. Cell Signal. 27(12), 2355–2362 (2015).Crossref, Medline, CAS, Google Scholar
22 Shurtleff MJ, Temoche-Diaz MM, Karfilis KV, Ri S, Schekman R. Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. Elife 5, pii: e19276 (2016).Crossref, Medline, Google Scholar
23 Buschow SI, Nolte-'t Hoen ENM, van Niel G et al. MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic 10(10), 1528–1542 (2009). http://doi.wiley.com/10.1111/j.1600-0854.2009.00963.x.Crossref, Medline, CAS, Google Scholar
24 Moreno-Gonzalo O, Villarroya-Beltri C, SÃ¡nchez-Madrid F. Post-translational modifications of exosomal proteins. Front. Immunol. 5, 383 (2014). http://journal.frontiersin.org/article/10.3389/fimmu.2014.00383/abstract.Crossref, Medline, Google Scholar
25 Kunadt M, Eckermann K, Stuendl A et al. Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation. Acta Neuropathol. 129(5), 695–713 (2015). http://link.springer.com/10.1007/s00401-015-1408-1.Crossref, Medline, CAS, Google Scholar
26 Géminard C, de Gassart A, Blanc L, Vidal M. Degradation of AP2 during reticulocyte maturation enhances binding of Hsc70 and alix to a common site on TfR for sorting into exosomes. Traffic 5(3), 181–193 (2004). http://doi.wiley.com/10.1111/j.1600-0854.2004.0167.x.Crossref, Medline, CAS, Google Scholar
27 Iavello A, Frech VSL, Gai C, Deregibus MC, Quesenberry PJ, Camussi G. Role of Alix in miRNA packaging during extracellular vesicle biogenesis. Int. J. Mol. Med. 37(4), 958–966 (2016).Crossref, Medline, CAS, Google Scholar
28 Zhu H, Guariglia S, Yu RYL et al. Mutation of SIMPLE in Charcot-Marie-Tooth 1C alters production of exosomes. Mol. Biol. Cell. 24(11), 1619–1637; S1–S3 (2013).Crossref, Medline, CAS, Google Scholar
29 Arenaccio C, Federico M. The multifaceted functions of exosomes in health and disease: an overview. Adv. Exp. Med. Biol. 993, 3–19 (2017). • Provides an overview of exosome composition, their interaction with bystander cells and their role in health and disease conditions as biomarkers and therapeutic delivery vehicles.Crossref, Medline, Google Scholar
30 Simpson RJ, Kalra H, Mathivanan S. Exocarta as a resource for exosomal research. J. Extracell. Vesicles 1(1), doi:10.3402/jev.v1i0.18374 (2012).Crossref, Medline, Google Scholar
31 Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 40(D1), D1241–D1244 (2012).Crossref, Medline, Google Scholar
32 Urbanelli L, Magini A, Buratta S et al. Signaling pathways in exosomes biogenesis, secretion and fate. Genes (Basel). 4(2), 152–170 (2013). www.ncbi.nlm.nih.gov/pubmed/24705158.Crossref, Medline, Google Scholar
33 Subra C, Laulagnier K, Perret B, Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 89(2), 205–212 (2007). www.ncbi.nlm.nih.gov/pubmed/17157973.Crossref, Medline, CAS, Google Scholar
34 Skotland T, Sandvig K, Llorente A. Lipids in exosomes: current knowledge and the way forward. Prog. Lipid Res. 66, 30–41 (2017). www.sciencedirect.com/science/article/pii/S0163782716300492.Crossref, Medline, CAS, Google Scholar
35 Vidal M, Sainte-Marie J, Philippot JR, Bienvenue A. Asymmetric distribution of phospholipids in the membrane of vesicles released during in vitro maturation of guinea pig reticulocytes: evidence precluding a role for “aminophospholipid translocase”. J. Cell. Physiol. 140(3), 455–462 (1989).Crossref, Medline, CAS, Google Scholar
36 Laulagnier K, Motta C, Hamdi S et al. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem. J. 380(Pt 1), 161–171 (2004).Crossref, Medline, CAS, Google Scholar
37 Needham D, Nunn RS. Elastic deformation and failure of lipid bilayer membranes containing cholesterol. Biophys. J. 58(4), 997–1009 (1990).Crossref, Medline, CAS, Google Scholar
38 Ramstedt B, Slotte JP. Membrane properties of sphingomyelins. FEBS Lett. 531(1), 33–37 (2002). www.sciencedirect.com/science/article/pii/S0014579302034063.Crossref, Medline, CAS, Google Scholar
39 Abi-Rizk G, Besson F. Interactions of Triton X-100 with sphingomyelin and phosphatidylcholine monolayers: influence of the cholesterol content. Colloids Surfaces B Biointerfaces. 66(2), 163–167 (2008).Crossref, Medline, CAS, Google Scholar
40 Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51(4), 691–743 (1999).Medline, CAS, Google Scholar
41 Schiffelers R, Kooijmans S, Vader SM, van Dommelen WW, Van Solinge RM. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomedicine 7, 1525 (2012). www.ncbi.nlm.nih.gov/pubmed/22619510.Crossref, Medline, Google Scholar
42 Yokoyama S, Takeda T, Tsunoda T, Ohta Y, Imura T, Abe M. Membrane properties of mixed dipalmitoylphosphatidylglycerol/ganglioside GM3 liposomes in the presence of bovine serum albumin. Colloids Surf. B 27(2–3), 141–146 (2003). www.sciencedirect.com/science/article/pii/S0927776502000498.Crossref, CAS, Google Scholar
43 Stace C, Ktistakis N. Phosphatidic acid- and phosphatidylserine-binding proteins. Biochim. Biophys. Acta 1761(8), 913–926 (2006). www.ncbi.nlm.nih.gov/pubmed/16624617.Crossref, Medline, Google Scholar
44 Schutters K, Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis. 15(9), 1072–1082 (2010).Crossref, Medline, CAS, Google Scholar
45 Parolini I, Federici C, Raggi C et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284(49), 34211–34222 (2009).Crossref, Medline, CAS, Google Scholar
46 Varnier A, Kermarrec F, Blesneac I et al. A simple method for the reconstitution of membrane proteins into giant unilamellar vesicles. J. Membr. Biol. 233(1–3), 85–92 (2010).Crossref, Medline, CAS, Google Scholar
47 Simpson RJ, Jensen SS, Lim JWE. Proteomic profiling of exosomes: current perspectives. Proteomics 8(19), 4083–4099 (2008). www.ncbi.nlm.nih.gov/pubmed/18780348.Crossref, Medline, CAS, Google Scholar
48 Raimondo F, Morosi L, Chinello C, Magni F, Pitto M. Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics 11(4), 709–720 (2011). www.ncbi.nlm.nih.gov/pubmed/21241021.Crossref, Medline, CAS, Google Scholar
49 Andreu Z, Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and function. Front. Immunol. 5, 442 (2014). http://journal.frontiersin.org/article/10.3389/fimmu.2014.00442/abstract.Crossref, Medline, Google Scholar
50 Théry C, Regnault A, Garin J et al. Molecular characterization of dendritic cell-derived exosomes: selective accumulation of the heat shock protein hsc73. J. Cell Biol. 147(3), 599–610 (1999).Crossref, Medline, CAS, Google Scholar
51 Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J. Biol. Chem. 273(32), 20121–20127 (1998).Crossref, Medline, CAS, Google Scholar
52 Atay S, Gercel-Taylor C, Kesimer M, Taylor DD. Morphologic and proteomic characterization of exosomes released by cultured extravillous trophoblast cells. Exp. Cell Res. 317(8), 1192–1202 (2011).Crossref, Medline, CAS, Google Scholar
53 Hemler ME. Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 6(10), 801–811 (2005).Crossref, Medline, CAS, Google Scholar
54 Espenel C, Margeat E, Dosset P et al. Single-molecule analysis of CD9 dynamics and partitioning reveals multiple modes of interaction in the tetraspanin web. J. Cell Biol. 182(4), 765–776 (2008). www.ncbi.nlm.nih.gov/pubmed/18710926.Crossref, Medline, CAS, Google Scholar
55 Charrin S, Jouannet S, Boucheix C, Rubinstein E. Tetraspanins at a glance. J. Cell Sci. 127(Pt 17), 3641–3648 (2014).Crossref, Medline, CAS, Google Scholar
56 Hemler ME. Targeting of tetraspanin proteins--potential benefits and strategies. Nat. Rev. Drug Discov. 7(9), 747–758 (2008).Crossref, Medline, CAS, Google Scholar
57 Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ. Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt signaling. J. Cell Biol. 190(6), 1079–1091 (2010). www.ncbi.nlm.nih.gov/pubmed/20837771.Crossref, Medline, CAS, Google Scholar
58 Tejera E, Rocha-Perugini V, López-Martín S et al. CD81 regulates cell migration through its association with Rac GTPase. Mol. Biol. Cell 24(3), 261–273 (2013). www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3564539&tool=pmcentrez&rendertype=abstract.Crossref, Medline, CAS, Google Scholar
59 Saiz ML, Rocha-Perugini V, Sánchez-Madrid F. Tetraspanins as organizers of antigen-presenting cell function. Front. Immunol. 9, 1074 (2018). www.ncbi.nlm.nih.gov/pubmed/29875769.Crossref, Medline, Google Scholar
60 van Dommelen SM, Vader P, Lakhal S et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J. Control. Release 161(2), 635–644 (2012). www.ncbi.nlm.nih.gov/pubmed/22138068.Crossref, Medline, CAS, Google Scholar
61 Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 339(1), 269–280 (2010). www.ncbi.nlm.nih.gov/pubmed/19693543.Crossref, Medline, CAS, Google Scholar
62 Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol. 3(3), a004994 (2011). www.ncbi.nlm.nih.gov/pubmed/21421922.Crossref, Medline, Google Scholar
63 Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 3(12), 1156–1162 (2002).Crossref, Medline, CAS, Google Scholar
64 Gonzales PA, Pisitkun T, Hoffert JD et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol. 20(2), 363–379 (2009).Crossref, Medline, CAS, Google Scholar
65 Gonzalez-Begne M, Lu B, Han X et al. Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). J. Proteome Res. 8(3), 1304–1314 (2009).Crossref, Medline, CAS, Google Scholar
66 Pisitkun T, Shen R-F, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc. Natl Acad. Sci. USA 101(36), 13368–13373 (2004).Crossref, Medline, CAS, Google Scholar
67 Looze C, Yui D, Leung L et al. Proteomic profiling of human plasma exosomes identifies PPARgamma as an exosome-associated protein. Biochem. Biophys. Res. Commun. 378(3), 433–438 (2009).Crossref, Medline, CAS, Google Scholar
68 Bard MP, Hegmans JP, Hemmes A et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell Mol. Biol. 31(1), 114–121 (2004).Crossref, Medline, CAS, Google Scholar
69 Mathivanan S, Lim JWE, Tauro BJ, Ji H, Moritz RL, Simpson RJ. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol. Cell. Proteomics. 9(2), 197–208 (2010).Crossref, Medline, CAS, Google Scholar
70 Xiao X, Mruk DD, Cheng CY. Intercellular adhesion molecules (ICAMs) and spermatogenesis. Hum. Reprod. Update 19(2), 167–186 (2013). www.ncbi.nlm.nih.gov/pubmed/23287428.Crossref, Medline, CAS, Google Scholar
71 Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654–659 (2007).Crossref, Medline, CAS, Google Scholar
72 Skokos D, Le Panse S, Villa I et al. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J. Immunol. 166(2), 868–876 (2001).Crossref, Medline, CAS, Google Scholar
73 Skokos D, Le Panse S, Villa I et al. Nonspecific B and T cell-stimulatory activity mediated by mast cells is associated with exosomes. Int. Arch. Allergy Immunol. 124(1–3), 133–136 (2001).Crossref, Medline, CAS, Google Scholar
74 Buschow SI, van Balkom BWM, Aalberts M, Heck AJR, Wauben M, Stoorvogel W. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunol. Cell Biol. 88(8), 851–856 (2010). http://dx.doi.org/10.1038/icb.2010.64.Crossref, Medline, CAS, Google Scholar
75 Long EO. ICAM-1: getting a grip on leukocyte adhesion. J. Immunol. 186(9), 5021–5023 (2011). www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3860744&tool=pmcentrez&rendertype=abstract.Crossref, Medline, CAS, Google Scholar
76 Segura E, Nicco C, Lombard B et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106(1), 216–223 (2005). www.ncbi.nlm.nih.gov/pubmed/15790784.Crossref, Medline, CAS, Google Scholar
77 Segura E, Guerin C, Hogg N, Amigorena S, Thery C. CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo. J. Immunol. 179(3), 1489–1496 (2007). www.jimmunol.org/cgi/doi/10.4049/jimmunol.179.3.1489.Crossref, Medline, CAS, Google Scholar
78 Švajger U, Anderluh M, Jeras M, Obermajer N. C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell. Signal. 22(10), 1397–1405 (2010). www.ncbi.nlm.nih.gov/pubmed/20363321.Crossref, Medline, CAS, Google Scholar
79 Clayton A, Harris CL, Court J, Mason MD, Morgan BP. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur. J. Immunol. 33(2), 522–531 (2003). www.ncbi.nlm.nih.gov/pubmed/12645951.Crossref, Medline, CAS, Google Scholar
80 Choi D-S, Park JO, Jang SC et al. Proteomic analysis of microvesicles derived from human colorectal cancer ascites. Proteomics. 11(13), 2745–2751 (2011).Crossref, Medline, CAS, Google Scholar
81 Kesimer M, Scull M, Brighton B et al. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J. 23(6), 1858–1868 (2009).Crossref, Medline, CAS, Google Scholar
82 Fevrier B, Vilette D, Archer F et al. Cells release prions in association with exosomes. Proc. Natl Acad. Sci. USA 101(26), 9683–9688 (2004).Crossref, Medline, CAS, Google Scholar
83 Potolicchio I, Carven GJ, Xu X et al. Proteomic analysis of microglia-derived exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. J. Immunol. 175(4), 2237–2243 (2005).Crossref, Medline, CAS, Google Scholar
84 Ji H, Erfani N, Tauro BJ et al. Difference gel electrophoresis analysis of Ras-transformed fibroblast cell-derived exosomes. Electrophoresis 29(12), 2660–2671 (2008).Crossref, Medline, CAS, Google Scholar
85 Zeelenberg IS, Ostrowski M, Krumeich S et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res. 68(4), 1228–1235 (2008).Crossref, Medline, CAS, Google Scholar
86 Hartman ZC, Wei J, Glass OK et al. Increasing vaccine potency through exosome antigen targeting. Vaccine 29(50), 9361–9367 (2011).Crossref, Medline, CAS, Google Scholar
87 Rountree RB, Mandl SJ, Nachtwey JM et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 71(15), 5235–5244 (2011).Crossref, Medline, CAS, Google Scholar
88 Lötvall J, Hill AF, Hochberg F et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 3(1), 10.3402/jev.v3.26913 (2014).Crossref, Google Scholar
89 Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2(1), 282 (2011).Crossref, Medline, Google Scholar
90 Ratajczak J, Miekus K, Kucia M et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20(5), 847–856 (2006).Crossref, Medline, CAS, Google Scholar
91 Pegtel DM, Cosmopoulos K, Thorley-Lawson DA et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. USA 107(14), 6328–6333 (2010). www.pnas.org/cgi/doi/10.1073/pnas.0914843107.Crossref, Medline, CAS, Google Scholar
92 Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res. 40(21), 10937–10949 (2012).Crossref, Medline, CAS, Google Scholar
93 Huang X, Yuan T, Tschannen M et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 14(1), 319 (2013).Crossref, Google Scholar
94 Vojtech L, Woo S, Hughes S et al. Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions. Nucleic Acids Res. 42(11), 7290–7304 (2014).Crossref, Medline, CAS, Google Scholar
95 Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Lett. 347(1), 29–37 (2014). www.ncbi.nlm.nih.gov/pubmed/24513178.Crossref, Medline, CAS, Google Scholar
96 Schageman J, Zeringer E, Li M et al. The complete exosome workflow solution: from isolation to characterization of RNA cargo. Biomed. Res. Int. 2013, 253957 (2013).Crossref, Medline, Google Scholar
97 Qin J, Xu Q. Functions and application of exosomes. Acta Pol. Pharm. 71(4), 537–543 (2014). www.ncbi.nlm.nih.gov/pubmed/25272880.Medline, Google Scholar
98 Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm. Sin. B 6(4), 287–296 (2016). www.ncbi.nlm.nih.gov/pubmed/27471669. • Emphasizes the exosome formation process, the isolation and the characterization of these exosomes and their biological function. Also, it reviewed exosomes as a delivery vehicle for proteins and nucleic acids and highlighted their major advantages and disadvantages to overcome any therapeutic challenges.Crossref, Medline, Google Scholar
99 Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94(11), 3791–3799 (1999). www.ncbi.nlm.nih.gov/pubmed/10572093.Crossref, Medline, CAS, Google Scholar
100 Ghidoni R, Benussi L, Binetti G. Exosomes: the Trojan horses of neurodegeneration. Med. Hypotheses 70(6), 1226–1227 (2008). www.ncbi.nlm.nih.gov/pubmed/18226468.Crossref, Medline, CAS, Google Scholar
101 Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70(23), 9621–9630 (2010).Crossref, Medline, CAS, Google Scholar
102 Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 15(3), 281–295 (2013). www.ncbi.nlm.nih.gov/pubmed/23479506.Crossref, Medline, CAS, Google Scholar
103 Kucharzewska P, Christianson HC, Welch JE et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl Acad. Sci. USA 110(18), 7312–7317 (2013). www.ncbi.nlm.nih.gov/pubmed/23589885.Crossref, Medline, CAS, Google Scholar
104 Sharma A. Role of stem cell derived exosomes in tumor biology. Int. J. Cancer 142(6), 1086–1092 (2018). www.ncbi.nlm.nih.gov/pubmed/28983919.Crossref, Medline, CAS, Google Scholar
105 Carretero-González A, Otero I, Carril-Ajuria L, de Velasco G, Manso L. Exosomes: definition, role in tumor development and clinical implications. Cancer Microenviron. (2018). www.ncbi.nlm.nih.gov/pubmed/29721824%0Ahttp://link.springer.com/10.1007/s12307-018-0211-7. • Highlighted the role of exosomes in oncogenesis, developing a premetastatic niche and their potential diagnostc and therapeutic applications.Crossref, Medline, Google Scholar
106 Kumar B, Garcia M, Weng L et al. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32(3), 575–587 (2018). www.ncbi.nlm.nih.gov/pubmed/28816238.Crossref, Medline, CAS, Google Scholar
107 Morelli AE, Larregina AT, Shufesky WJ et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 104(10), 3257–3266 (2004). www.ncbi.nlm.nih.gov/pubmed/15284116.Crossref, Medline, CAS, Google Scholar
108 De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front. Immunol. 6 , 203 (2015). http://journal.frontiersin.org/Article/10.3389/fimmu.2015.00203/abstract.Medline, Google Scholar
109 Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 67(7), 2912–2915 (2007). www.ncbi.nlm.nih.gov/pubmed/17409393.Crossref, Medline, CAS, Google Scholar
110 Liu Y, Gu Y, Cao X. The exosomes in tumor immunity. Oncoimmunology 4(9), 1–8 (2015).Crossref, Google Scholar
111 Yang C, Kim SH, Bianco NR, Robbins PD. Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. PLoS ONE 6(8), e22517 (2011).Crossref, Google Scholar
112 Valenti R, Huber V, Filipazzi P et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Res. 66(18), 9290–9298 (2006). http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-06-1819.Crossref, Medline, CAS, Google Scholar
113 Czernek L, Düchler M. Functions of cancer-derived extracellular vesicles in immunosuppression. Arch. Immunol. Ther. Exp. (Warsz). 65(4), 311–323 (2017). www.ncbi.nlm.nih.gov/pubmed/28101591. • This review explaind how cancer cells escape the immune system through their cancer-derived exosomes and also the role of these exosomes in immune system stimulation.Crossref, Medline, CAS, Google Scholar
114 Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS ONE 6(2), e16899 (2011). www.ncbi.nlm.nih.gov/pubmed/21364924.Crossref, Medline, CAS, Google Scholar
115 Wolfers J, Lozier A, Raposo G et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7(3), 297–303 (2001). www.ncbi.nlm.nih.gov/pubmed/11231627.Crossref, Medline, CAS, Google Scholar
116 Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of peripheral humanT cells detected by ELISPOT. Eur. J. Immunol. 36(7), 1772–1781 (2006). www.ncbi.nlm.nih.gov/pubmed/16761310.Crossref, Medline, CAS, Google Scholar
117 Admyre C, Bohle B, Johansson SM et al. B cell–derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. J. Allergy Clin. Immunol. 120(6), 1418–1424 (2007). www.ncbi.nlm.nih.gov/pubmed/17868797.Crossref, Medline, CAS, Google Scholar
118 Andre F, Schartz NE, Movassagh M et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360(9329), 295–305 (2002). www.ncbi.nlm.nih.gov/pubmed/12147373.Crossref, Medline, CAS, Google Scholar
119 Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J. Biol. Chem. 280(24), 23349–23355 (2005). http://www.ncbi.nlm.nih.gov/pubmed/15826944.Crossref, Medline, CAS, Google Scholar
120 Barros FM, Carneiro F, Machado JC, Melo SA. Exosomes and immune response in cancer: friends or foes? Front. Immunol. 9, 730 (2018). www.ncbi.nlm.nih.gov/pubmed/29696022.Crossref, Medline, Google Scholar
121 Lugini L, Cecchetti S, Huber V et al. Immune surveillance properties of human NK cell-derived exosomes. J. Immunol. 189(6), 2833–2842 (2012). www.ncbi.nlm.nih.gov/pubmed/22904309.Crossref, Medline, CAS, Google Scholar
122 Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci. Rep. 6(1), 20254 (2016). www.nature.com/articles/srep20254.Crossref, Medline, CAS, Google Scholar
123 Mrizak D, Martin N, Barjon C et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J. Natl. Cancer Inst. 107(1), 363 (2015). https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju363.Crossref, Medline, Google Scholar
124 Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 5(7), e11469 (2010). www.ncbi.nlm.nih.gov/pubmed/20661468.Crossref, Medline, Google Scholar
125 Chalmin F, Ladoire S, Mignot G et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120(2), 457–471 (2010).Medline, CAS, Google Scholar
126 Xiang X, Poliakov A, Liu C et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124(11), 2621–2633 (2009).Crossref, Medline, CAS, Google Scholar
127 Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 67(15), 7458–7466 (2007). http://cancerres.aacrjournals.org/content/67/15/7458.short.Crossref, Medline, CAS, Google Scholar
128 Hong C-S, Sharma P, Yerneni SS et al. Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia. Sci. Rep. 7(1), 14684 (2017). http://www.nature.com/articles/s41598-017-14661-w.Crossref, Medline, Google Scholar
129 Andreola G, Rivoltini L, Castelli C et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195(10), 1303–1316 (2002). http://www.ncbi.nlm.nih.gov/pubmed/12021310.Crossref, Medline, CAS, Google Scholar
130 Clayton A, Mason MD. Exosomes in tumour immunity. Curr. Oncol. 16(3), 46–49 (2009). www.ncbi.nlm.nih.gov/pubmed/19526085.Crossref, Medline, CAS, Google Scholar
131 Haderk F, Schulz R, Iskar M et al. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci. Immunol. 2(13), eaah5509 (2017). www.ncbi.nlm.nih.gov/pubmed/28754746.Crossref, Medline, Google Scholar
132 Wang F, Li B, Wei Y et al. Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression. Oncogenesis 7(5), 41 (2018). /www.nature.com/articles/s41389-018-0049-3.Crossref, Medline, Google Scholar
133 Yang N, Li S, Li G et al. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget. (2015).Google Scholar
134 Grange C, Tapparo M, Collino F et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71(15), 5346–5356 (2011). www.ncbi.nlm.nih.gov/pubmed/21670082.Crossref, Medline, CAS, Google Scholar
135 Conigliaro A, Costa V, Lo Dico A et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol. Cancer. 14(1), 155 (2015).Crossref, Medline, Google Scholar
136 Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. pp.jbc-M113 (2013).Crossref, Medline, Google Scholar
137 Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 124(25), 3748–3457 (2014). www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4263983&tool=pmcentrez&rendertype=abstract.Crossref, Medline, CAS, Google Scholar
138 Hsu YL, Hung JY, Chang WA et al. Hypoxic lung cancer-secreted exosomal MIR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene 36(34), 4929 (2017).Crossref, Medline, CAS, Google Scholar
139 Da Forno PD, Pringle JH, Hutchinson P et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. 14(18), 5825–5832 (2008). www.ncbi.nlm.nih.gov/pubmed/18794093.Crossref, Medline, CAS, Google Scholar
140 Ekström EJ, Bergenfelz C, von Bülow V et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol. Cancer 13(1), 88 (2014). http://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-88.Crossref, Medline, Google Scholar
141 Gopal SK, Greening DW, Hanssen EG, Zhu H-J, Simpson RJ, Mathias RA. Oncogenic epithelial cell-derived exosomes containing Rac1 and PAK2 induce angiogenesis in recipient endothelial cells. Oncotarget 7(15), 19709–19722 (2016). www.ncbi.nlm.nih.gov/pubmed/26919098.Crossref, Medline, Google Scholar
142 Liu Y, Luo F, Wang B et al. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 370(1), 125–135 (2016). www.ncbi.nlm.nih.gov/pubmed/26525579.Crossref, Medline, CAS, Google Scholar
143 Chan YK, Zhang H, Liu P et al. Proteomic analysis of exosomes from nasopharyngeal carcinoma cell identifies intercellular transfer of angiogenic proteins. Int. J. Cancer. (2015).Crossref, Google Scholar
144 Tang MKS, Yue PYK, Ip PP et al. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nat. Commun. 9(1), 2270 (2018).Crossref, Medline, Google Scholar
145 Chiba M, Kubota S, Sato K, Monzen S. Exosomes released from pancreatic cancer cells enhance angiogenic activities via dynamin-dependent endocytosis in endothelial cells in vitro. Sci. Rep. 8(1), 11972 (2018).Crossref, Medline, Google Scholar
146 Lang H-L, Hu G-W, Chen Y et al. Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3. Eur. Rev. Med. Pharmacol. Sci. 21(5), 959–972 (2017).Medline, Google Scholar
147 Roma-Rodrigues C, Fernandes AR, Baptista PV. Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells. Biomed Res. Int. 2014, 179486 (2014). www.ncbi.nlm.nih.gov/pubmed/24963475.Medline, Google Scholar
148 Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 9(1), 244 (2009). www.ncbi.nlm.nih.gov/pubmed/19619303.Crossref, Medline, Google Scholar
149 Hoshino A, Costa-Silva B, Shen T-L et al. Tumour exosome integrins determine organotropic metastasis. Nature 527(7578), 329–335 (2015).Crossref, Medline, Google Scholar
150 Chen CL, Lai YF, Tang P et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J. Proteome Res. 11(12), 5611–5629 (2012).Crossref, Medline, CAS, Google Scholar
151 Kannan A, Wells RB, Sivakumar S et al. Mitochondrial reprogramming regulates breast cancer progression. Clin. Cancer Res. 22(13), 3348–3360 (2016).Crossref, Medline, CAS, Google Scholar
152 Moon P-G, Lee J-E, Cho Y-E et al. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. Oncotarget 7(26), 40189–40199 (2016). www.ncbi.nlm.nih.gov/pubmed/27250024.Crossref, Medline, Google Scholar
153 Moon P-G, Lee J-E, Cho Y-E et al. Identification of developmental endothelial locus-1 on circulating extracellular vesicles as a novel biomarker for early breast cancer detection. Clin. Cancer Res. 22(7), 1757–1766 (2016). www.ncbi.nlm.nih.gov/pubmed/26603257.Crossref, Medline, CAS, Google Scholar
154 Logozzi M, Angelini DF, Iessi E et al. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett. 403, 318–329 (2017).Crossref, Medline, CAS, Google Scholar
155 Sun Y, Liu S, Qiao Z et al. Systematic comparison of exosomal proteomes from human saliva and serum for the detection of lung cancer. Anal. Chim. Acta 982, 84–95 (2017). http://www.ncbi.nlm.nih.gov/pubmed/28734369.Crossref, Medline, CAS, Google Scholar
156 He M, Qin H, Poon TCW et al. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs. Carcinogenesis 36(9), 1008–1018 (2015). https://academic.oup.com/carcin/article-lookup/doi/10.1093/carcin/bgv081.Crossref, Medline, CAS, Google Scholar
157 Bosque A, Dietz L, Gallego-Lleyda A et al. Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. Oncotarget 7(20), 29287–29305 (2016). www.ncbi.nlm.nih.gov/pubmed/27086912.Crossref, Medline, Google Scholar
158 Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997–1006 (2008). http://dx.doi.org/10.1038/cr.2008.282.Crossref, Medline, CAS, Google Scholar
159 Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513–10518 (2008). www.pnas.org/content/105/30/10513.Crossref, Medline, CAS, Google Scholar
160 Nilsson J, Skog J, Nordstrand A et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100(10), 1603–1607 (2009).Crossref, Medline, CAS, Google Scholar
161 Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 1820(7), 940–948 (2012). www.sciencedirect.com/science/article/pii/S0304416512000906.Crossref, Medline, CAS, Google Scholar
162 Armstrong DA, Green BB, Seigne JD, Schned AR, Marsit CJ. MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol. Cancer 14(1), 194 (2015).Crossref, Medline, Google Scholar
163 Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin. Chem. 57(1), 18–32 (2010).Crossref, Medline, Google Scholar
164 Halvorsen AR, Bjaanaes M, LeBlanc M et al. A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget 7(24), 37250–37259 (2016). www.ncbi.nlm.nih.gov/pubmed/27191990%5Cn.Crossref, Medline, Google Scholar
165 Tanaka Y, Kamohara H, Kinoshita K et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119(6), 1159–1167 (2013).Crossref, Medline, CAS, Google Scholar
166 Cazzoli R, Buttitta F, Di Nicola M et al. MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J. Thorac. Oncol. 8(9), 1156–1162 (2013).Crossref, Medline, CAS, Google Scholar
167 Joshi GK, Deitz-McElyea S, Liyanage T et al. Label-free nanoplasmonic-based short noncoding RNA sensing at attomolar concentrations allows for quantitative and highly specific assay of microRNA-10b in biological fluids and circulating exosomes. ACS Nano. 9(11), 11075–11089 (2015).Crossref, Medline, CAS, Google Scholar
168 Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett. 393, 86–93 (2017). www.ncbi.nlm.nih.gov/pubmed/28232049.Crossref, Medline, CAS, Google Scholar
169 Li J, Chen Y, Guo X et al. GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer. J. Cell. Mol. Med. 21(5), 838–847 (2017). www.ncbi.nlm.nih.gov/pubmed/28233416.Crossref, Medline, CAS, Google Scholar
170 Bobrie A, Krumeich S, Reyal F et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 72(19), 4920–4930 (2012). www.ncbi.nlm.nih.gov/pubmed/22865453.Crossref, Medline, CAS, Google Scholar
171 Ruiz-Martinez M, Navarro A, Marrades RM et al. YKT6 expression, exosome release, and survival in non-small cell lung cancer. Oncotarget 7(32), 51515–51524 (2016). www.ncbi.nlm.nih.gov/pubmed/27285987.Crossref, Medline, Google Scholar
172 Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341–345 (2011).Crossref, Medline, CAS, Google Scholar
173 Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13–21 (2008). www.sciencedirect.com/science/article/pii/S0090825808003430.Crossref, Medline, CAS, Google Scholar
174 Tan A, Yildirimer L, Rajadas J, De La Peña H, Pastorin G, Seifalian A. Quantum dots and carbon nanotubes in oncology: a review on emerging theranostic applications in nanomedicine. Nanomedicine 6(6), 1101–1114 (2011). www.ncbi.nlm.nih.gov/pubmed/21955079.Crossref, Medline, Google Scholar
175 Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 1846(1), 75–87 (2014). www.sciencedirect.com/science/article/pii/S0304419X14000419.Medline, CAS, Google Scholar
176 Raimondi L, De Luca A, Amodio N et al. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget 6(15), 13772 (2015). www.ncbi.nlm.nih.gov/pubmed/25944696.Crossref, Medline, Google Scholar
177 Gutzeit C, Nagy N, Gentile M et al. Exosomes derived from Burkitt's lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells. J. Immunol. 192(12), 5852–5862 (2014). www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4174405&tool=pmcentrez&rendertype=abstract.Crossref, Medline, CAS, Google Scholar
178 Harris DA, Patel SH, Gucek M, Hendrix A, Westbroek W, Taraska JW. Exosomes released from breast cancer carcinomas stimulate cell movement. PLoS ONE 10(3), e0117495 (2015). http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0117495.Crossref, Medline, Google Scholar
179 Escudier B, Dorval T, Chaput N et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first Phase I clinical trial. J. Transl. Med. 3(1), 10 (2005). www.translational-medicine.com/content/3/1/10.Crossref, Medline, Google Scholar
180 Morse MA, Garst J, Osada T et al. A Phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 3, 9 (2005).Crossref, Medline, Google Scholar
181 Dai S, Wei D, Wu Z et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 16(4), 782–790 (2008). www.ncbi.nlm.nih.gov/pubmed/18362931.Crossref, Medline, CAS, Google Scholar
182 Lundholm M, Schröder M, Nagaeva O et al. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS ONE 9(9), e108925 (2014). http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108925.Crossref, Medline, Google Scholar
183 Obeid MA, Elburi A, Young LC, Mullen AB, Tate RJ, Ferro VA. Formulation of Nonionic Surfactant Vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells. Mol. Pharm. 14(7), 2450–2458 (2017). www.ncbi.nlm.nih.gov/pubmed/28570823.Crossref, Medline, CAS, Google Scholar
184 Tan A, Rajadas J, Seifalian AM. Exosomes as nano-theranostic delivery platforms for gene therapy. Adv. Drug Deliv. Rev. 65(3), 357–367 (2013). www.ncbi.nlm.nih.gov/pubmed/22820532. •• An overview of exosome nucleic acids and their contribution as diagnostic tools and therapeutic approachs in nanomedicine.Crossref, Medline, CAS, Google Scholar
185 Obeid MA, Tate RJ, Mullen AB, Ferro VA. Lipid-based nanoparticles for cancer treatment. Lipid Nanocarriers Drug Target. 313–359 (2018). www.sciencedirect.com/science/article/pii/B9780128136874000086.Crossref, Google Scholar
186 Obeid MA, Dufès C, Somani S, Mullen AB, Tate RJ, Ferro VA. Proof of concept studies for siRNA delivery by non-ionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown. J. Liposome Res. 1–27 (2018). www.tandfonline.com/doi/full/10.1080/08982104.2018.1531424.Crossref, Medline, Google Scholar
187 Akao Y, Iio A, Itoh T et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol. Ther. 19(2), 395–399 (2011). www.ncbi.nlm.nih.gov/pubmed/21102562.Crossref, Medline, CAS, Google Scholar
188 Kogure T, Lin W-L, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 54(4), 1237–1248 (2011). http://doi.wiley.com/10.1002/hep.24504.Crossref, Medline, CAS, Google Scholar
189 Takeshita F, Patrawala L, Osaki M et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18(1), 181–187 (2010). www.ncbi.nlm.nih.gov/pubmed/19738602.Crossref, Medline, CAS, Google Scholar
190 Clapé C, Fritz V, Henriquet C et al. miR-143 Interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 4(10), e7542 (2009). http://dx.plos.org/10.1371/journal.pone.0007542.Crossref, Medline, Google Scholar
191 O'Brien K, Lowry MC, Corcoran C et al. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 6(32), 32774–32789 (2015). www.oncotarget.com/fulltext/5192.Crossref, Medline, Google Scholar
192 Greco KA, Franzen CA, Foreman KE, Flanigan RC, Kuo PC, Gupta GN. PLK-1 silencing in bladder cancer by siRNA delivered with exosomes. Urology 91, 241e1–241e7 (2016).Crossref, Google Scholar
193 Aqil F, Kausar H, Agrawal AK et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp. Mol. Pathol. 101(1), 12–21 (2016).Crossref, Medline, CAS, Google Scholar
194 Yang T, Martin P, Fogarty B et al. Exosome delivered anticancer drugs across the blood–brain barrier for brain cancer therapy in Danio Rerio. Pharm. Res. 32(6), 2003–2014 (2015). http://link.springer.com/10.1007/s11095-014-1593-y.Crossref, Medline, CAS, Google Scholar
195 Obeid MA, Al Qaraghuli MM, Alsaadi M, Alzahrani AR, Niwasabutra K, Ferro VA. Delivering natural products and biotherapeutics to improve drug efficacy. Ther. Deliv. 8(11), 947–956 (2017).Link, CAS, Google Scholar
196 Ohno S, Takanashi M, Sudo K et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21(1), 185–191 (2013). www.ncbi.nlm.nih.gov/pubmed/23032975.Crossref, Medline, CAS, Google Scholar
197 Tian Y, Li S, Song J et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35(7), 2383–2390 (2014). www.ncbi.nlm.nih.gov/pubmed/24345736.Crossref, Medline, CAS, Google Scholar
198 Hudry E, Martin C, Gandhi S et al. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 23(4), 380–392 (2016). www.nature.com/articles/gt201611.Crossref, Medline, CAS, Google Scholar
199 Lv L-H, Wan Y-L, Lin Y et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J. Biol. Chem. 287(19), 15874–15885 (2012). www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3346092&tool=pmcentrez&rendertype=abstract.Crossref, Medline, CAS, Google Scholar
200 Xie Y, Bai O, Zhang H et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J. Cell. Mol. Med. 14(11), 2655–2666 (2010). www.ncbi.nlm.nih.gov/pubmed/19627400.Crossref, Medline, CAS, Google Scholar
201 Barbuto JAM, Ensina LFC, Neves AR et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. 53(12), 1111–1118 (2004).Crossref, Medline, Google Scholar
202 Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113(11), 1515–1525 (2004).Crossref, Medline, CAS, Google Scholar
203 Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29(6), 371–380 (1996). www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8977634.Crossref, Medline, CAS, Google Scholar
204 Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 328–332 (1998).Crossref, Medline, CAS, Google Scholar
205 Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265–277 (2012). www.ncbi.nlm.nih.gov/pubmed/22437871.Crossref, Medline, CAS, Google Scholar
206 Wang K, Zhou Q, Guo AL, Xu CR, An SJ, Wu YL. An autologous therapeutic dendritic cell vaccine transfected with total lung carcinoma rna stimulates cytotoxic t lymphocyte responses against non-small cell lung cancer. Immunol. Invest. 38(7), 665–680 (2009).Crossref, Medline, CAS, Google Scholar
207 Romagnoli GG, Zelante BB, Toniolo PA, Migliori IK, Barbuto JAM. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front. Immunol. 5, 692 (2015).Crossref, Medline, Google Scholar
208 Amigorena S. Cancer immunotherapy using dendritic cell-derived exosomes. Medicina. 60(Suppl. 2), 51–54 (2000).Medline, CAS, Google Scholar
209 Goetzl EJ, Goetzl L, Karliner JS, Tang N, Pulliam L. Human plasma platelet-derived exosomes: effects of aspirin. FASEB J. 30(5), 2058–2063 (2016).Crossref, Medline, CAS, Google Scholar
210 Kapustin AN, Chatrou MLL, Drozdov I et al. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ. Res. 116(8), 1312–1323 (2015).Crossref, Medline, CAS, Google Scholar
211 Shimbo K, Miyaki S, Ishitobi H et al. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem. Biophys. Res. Commun. 445(2), 381–387 (2014). www.sciencedirect.com/science/article/pii/S0006291X14002502.Crossref, Medline, CAS, Google Scholar
212 Federici C, Petrucci F, Caimi S et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS ONE 9(2), e88193 (2014).Crossref, Google Scholar
213 Kim MS, Haney MJ, Zhao Y et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12(3), 655–664 (2016).Crossref, Medline, CAS, Google Scholar
214 Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids 2, e126 (2013).Crossref, Medline, Google Scholar
215 Jang SC, Kim OY, Yoon CM et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7(9), 7698–7710 (2013). http://pubs.acs.org/doi/abs/10.1021/nn402232g.Crossref, Medline, CAS, Google Scholar
216 Qi H, Liu C, Long L et al. Blood exosomes endowed with magnetic and targeting properties for cancer therapy. ACS Nano. 10(3), 3323–3333 (2016).Crossref, Medline, CAS, Google Scholar
217 Munagala R, Aqil F, Jeyabalan J, Gupta RC. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 371(1), 48–61 (2016).Crossref, Medline, CAS, Google Scholar

Vol. 10, No. 1

Metrics

Downloaded 163 times

History

Received 31 July 2018

Accepted 23 October 2018

Published online 7 December 2018

Published in print January 2019

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

For studies involving data relating to human or animal experimental investigations, the authors should obtain appropriate institutional review board approval and state this within the article (for those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed). In addition, for investigations involving human subjects, the authors should obtain informed consent from the participants involved and include an explanation of how this was obtained in the manuscript. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Author contributions

All authors contributed equally to (a) substantial contributions to the conception or design of the work; (b) drafting the work; and (c) final approval of the version to be published; and (d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

PDF download

Exosomes: fighting cancer with cancer

Abstract

References